Modelling disease progression in Alzheimer's disease: A review of modelling methods used for cost-effectiveness analysis

PharmacoEconomics

Volumn 25, Issue 9, 2007, Pages 735-750

  Green, Colin ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GALANTAMINE; HUMANS; INDANS; MEMANTINE; MODELS, ECONOMIC; PHENYLCARBAMATES; PIPERIDINES;

EID: 34748901423     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725090-00003     Document Type: Review

References (69)

1. Loveman E, Green C, Kirby J, et al. The clinical and cost effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease. Health Technol Assess 2006; 10 (1): 1-176
2. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. The Cochrane Library, Issue 1. Chichester: John Wiley & Sons, Ltd, 2004
3. Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. The Cochrane Library, Issue 1. Chichester: John Wiley & Sons, Ltd, 2004
4. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2001; (4): CD001747
5. National Institute for Health and Clinical Excellence. Appraisal consultation document: donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease [online]. Available from URL: http://guidance.nice.org.uk/page.aspx?o=245908 [Accessed 2006 Jul 31]
6. Kirby J, Green C, Loveman E, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately-severe to severe Alzheimer's disease. Drugs Aging 2006; 23 (3): 227-40
7. Lanctot KL, Risebrough N, Oh PI. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer's disease [abstract]. J Clin Pharmacol 1998; 38: 870
8. Sobolewski M, Kuzniar J, Splawinski J. Is donepezil cost-effective in the treatment of Alzheimer's disease? [abstract] Neurobiol Aging 2002; 23 (1): 368
9. Brooks E, Deal L. The effect of rivastigmine on the direct and indirect costs of Alzheimer's disease [abstract]. Value Health 2000; 3 (2): 79
10. Antonanzas F, Badenas J, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain [abstract]. Value Health 2003; 6 (6): 765
11. Guilhaume C. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Finland. Eur J Neurol 2003 Sep; 10 Suppl. 1: 159-60
12. Launois R, Guilhaume C, Francois C, et al. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Norway [abstract]. International Conference on Alzheimer's and Parkinson's Diseases; 2003 May 8-12; Seville
13. Stein K. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) [report no. 69]. Bristol: NHS Executive South and West, 1997
14. Stein K. Rivastigmine (Exelon) in the treatment of senile dementia of the Alzheimer type (SDAT) [report no. 89]. Bristol: NHS Executive South and West, 1998
15. Foster RH, Plosker GL. Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999 Jul; 16 (1): 99-114
16. Lyseng-Williamson K, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2002; 20 (13): 919-42
17. Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001; 19 (3): 303-18
18. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005; 23 (2): 193-206
19. Clegg A, Bryant J, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5 (1): 1-137
20. Wolfson C, Oremus M, Shukla V, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002 Jun; 24 (6): 862-86
21. Caro J, Salas M, Ward A, et al. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging 2004; 21 (10): 677-86
22. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 1998; 13 (7): 445-53
23. Jonsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999; 21 (7): 1230-40
24. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570-8
25. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999 Jun; 52 (6): 1138-45
26. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 2002; 13 (1): 33-9
27. Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 2003; 17 (1-2): 5-13
28. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial [published erratum appears in Dement Geriatr Cogn Disord 2003; 16 (2): 102]. Dement Geriatr Cogn Disord 2003; 15 (1): 44-54
29. AD2000 collaborative group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15
30. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer's disease: a modelling approach. Pharmacoeconomics 1999; 16 (2): 165-74
31. Hauber AB, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease: treatment with rivastigmine. Pharmacoeconomics 2000; 17 (4): 351-60
32. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000 Apr; 22 (4): 439-51
33. Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. AHEAD Study Group. Neurology 2001 Sep 25; 57 (6): 972-8
34. Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20 (9): 629-37
35. Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD) based on need for full-time care. Neurology 2001; 57 (6): 964-71
36. Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003 Jun; 25 (6): 1806-25
37. Ward A, Caro JJ, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003 Aug; 18 (8): 740-7
38. Caro J, Getsios D, Migliaccio-Walle K, et al. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer. BMC Geriatr 2003; 3 (6)
39. Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2005; 23 (12): 1271-82
40. François C, Sintonen H, Sulkava R. The cost-effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin Drug Investig 2004; 27 (7): 373-84
41. Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004 Jan; 19 (1): 58-67
42. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005; 3 (2): 77-86
43. Miners AH, Garau M, Fidan D, et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 2005; 330 (7482): 65
44. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomised drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-8
45. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-70
46. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
47. Drummond M, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 Aug 3; 313 (7052): 275-83
48. Philips Z, Ginnelly L, Sculpher M, et al. A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): iii-iv, ix-xi, 1-158
49. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-58
50. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
51. Rosler M, Anand R, Cicin SA, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318 (7184): 633-40
52. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1 (2): 55-65
53. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997 Mar 12; 277 (10): 806-12
54. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 Apr 3; 348 (14): 1333-41
55. Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care. The LASER-AD Study. Curr Med Res Opin 2004; S7: 1007-16
56. Fratiglioni L, Viitanen M, Backman L, et al. Occurrence of dementia in advanced age: the study design of the Kungsholm Project. Neuroepidemiology 1992; 11 Suppl. 1: 29-69
57. Neumann PJ, Araki SS, Arcelus A, et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 2001 Sep 25; 57 (6): 957-64
58. Mendiondo MS, Ashford JW, Kryscio RJ, et al. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 2000 Jun 15; 19 (11-12): 1607-16
59. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989 Sep; 39 (9): 1159-65
60. Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatments? Lancet 1999 Oct 30; 354 (9189): 1527-8
61. Davey RJ, Jamieson S. The validity of using the Mini Mental State Examination in NICE dementia guidelines. J Neurol Neurosurg Psychiatry 2004 Feb; 75 (2): 343-4
62. Tombaugh TN, Mcintyre NJ. The Mini-Mental-State-Examination: a comprehensive review. J Am Geriatr Soc 1992; 40 (9): 922-35
63. Wolstenholme J, Fenn P, Gray A, et al. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002; 181: 36-42
64. Clark CM, Sheppard L, Fillenbaum G, et al. Variability in Annual Mini-Mental State Examination score in patients with probable Alzheimer's disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999; 56: 857-62
65. Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999 Jan; 37 (1): 27-32
66. Andersen K, Nielsen H, Lolk A, et al. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: the Odense Study. Neurology 1999 Jan 1; 52 (1): 85-90
67. Andersen CK, Wittrup-Jensen KU, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004; 2 (52)
68. Caro JJ, Salas M, Ward A, et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14 (2): 84-9
69. Knapp M, Wilkinson D, Wigglesworth R. The economic consequences of Alzheimer's disease in the context of new drug developments. Int J Geriatr Psychiatry 1998 Feb; 13 (8): 531-43